Nvidia’s results, Indian tariffs, French markets - what’s moving markets
West Pharmaceutical Services Inc (NYSE:WST). stock has touched a 52-week low, dipping to $247.72, marking a significant downturn for the company within the past year. According to InvestingPro data, despite the company’s traditionally low price volatility, the stock currently trades at a premium valuation with a P/E ratio of ~47x. Analysts maintain a bullish outlook, with price targets ranging from $305 to $470. This latest price level reflects a notable decline in investor confidence as the stock has experienced a 1-year change with a decrease of 21.05%. The drop to this year’s low suggests a period of bearish sentiment surrounding the stock, as shareholders and potential investors are closely monitoring the company’s performance for signs of a turnaround or further decline. Despite the recent price weakness, the company maintains strong fundamentals with a healthy financial profile, earning a "GOOD" overall health score. Discover 12 more exclusive insights and detailed valuation analysis in the comprehensive Pro Research Report, available on InvestingPro.
In other recent news, West Pharmaceutical (TADAWUL:2070) Services reported fourth-quarter earnings and revenue that surpassed analyst expectations. The company posted adjusted earnings per share of $1.82, beating the analyst consensus of $1.72, and reported revenue of $748.8 million, which exceeded expectations of $740.75 million. This represented a 2.3% year-over-year increase, and organic net sales also grew by 3.3% compared to the same period last year.
Despite these positive results, West Pharma’s outlook for 2025 fell short of estimates, disappointing investors. The company forecasts full-year 2025 revenue between $2.875 billion and $2.905 billion, lower than the $3.04 billion analysts were expecting. Adjusted EPS guidance of $6.00 to $6.20 also did not meet the $7.43 consensus estimate.
For the full year 2024, the company reported net sales of $2.893 billion, a 1.9% decline year-over-year, and adjusted EPS fell 16.5% to $6.75. West Pharma anticipates organic net sales growth of 2% to 3% in 2025, despite a $75 million impact from foreign currency exchange rates. The company also plans to invest $275 million in capital spending for 2025 to support capacity expansions and investments in contract manufacturing facilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.